Valion Bio, Inc. Common Stock (NASDAQ:VBIO) Short Interest Update

Valion Bio, Inc. Common Stock (NASDAQ:VBIOGet Free Report) saw a large decline in short interest during the month of June. As of June 30th, there was short interest totaling 155,235 shares, a decline of 40.4% from the June 15th total of 260,360 shares. Currently, 5.0% of the shares of the stock are short sold. Based on an average daily volume of 252,050 shares, the days-to-cover ratio is currently 0.6 days.

Valion Bio, Inc. Common Stock Trading Up 8.3%

Shares of VBIO stock opened at $0.49 on Friday. Valion Bio, Inc. Common Stock has a twelve month low of $0.40 and a twelve month high of $5.60. The stock’s fifty day simple moving average is $0.68 and its 200 day simple moving average is $0.92. The company has a quick ratio of 3.02, a current ratio of 3.31 and a debt-to-equity ratio of 0.62. The firm has a market capitalization of $1.56 million, a P/E ratio of -0.07 and a beta of 1.82.

Valion Bio, Inc. Common Stock (NASDAQ:VBIOGet Free Report) last posted its earnings results on Thursday, May 14th. The company reported ($2.23) EPS for the quarter.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Valion Bio, Inc. Common Stock in a research note on Monday, April 20th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock has an average rating of “Sell”.

View Our Latest Research Report on Valion Bio, Inc. Common Stock

Valion Bio, Inc. Common Stock Company Profile

(Get Free Report)

Tivic Health Systems is a commercial-stage medical technology company that develops and markets non-drug, neuromodulation-based therapies for nasal and sinus health. The company’s solutions are designed to alleviate sinus pain, pressure and congestion through gentle microcurrent and vibration stimulation. By targeting the underlying nerve pathways in the nasal passages, Tivic Health aims to provide an alternative to over-the-counter and prescription medications without introducing systemic side effects.

The flagship product, ClearUP™ Sinus Pain Relief, is an FDA-cleared, hand-held device intended for home use.

See Also

Receive News & Ratings for Valion Bio Inc. Common Stock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valion Bio Inc. Common Stock and related companies with MarketBeat.com's FREE daily email newsletter.